T cell differentiation in chronic infection and cancer: Functional adaptation or exhaustion?

Nature Reviews Immunology

Volumn 14, Issue 11, 2014, Pages 768-774

  Speiser, Daniel E ^a   Utzschneider, Daniel T ^b   Oberle, Susanne G ^b   Münz, Christian ^c   Romero, Pedro ^a   Zehn, Dietmar ^b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PROGRAMMED DEATH 1 RECEPTOR; CYTOKINE; PDCD1 PROTEIN, HUMAN;

ADAPTATION; EFFECTOR CELL; INFECTION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; MEMORY T LYMPHOCYTE; NEOPLASM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; BIOSYNTHESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CHRONIC DISEASE; CYTOLOGY; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; SECRETION (PROCESS); VIRUS INFECTION;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CHRONIC DISEASE; CYTOKINES; HUMANS; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; VIRUS DISEASES;

EID: 84922394653     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3740     Document Type: Review

References (99)

1. Murali-Krishna, K. et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 8, 177-187 (1998).
2. + T cell response to infection. Immunity 26, 827-841 (2007).
3. + T cell responses to smallpox and yellow fever vaccines. Immunity 28, 710-722 (2008).
4. + T cell differentiation. Nature Rev. Immunol. 12, 749-761 (2012).
5. Arens, R. & Schoenberger, S. P. Plasticity in programming of effector and memory CD8 T-cell formation. Immunol. Rev. 235, 190-205 (2010).
6. + T cells: foot soldiers of the immune system. Immunity 35, 161-168 (2011).
7. Zehn, D., King, C., Bevan, M. J. & Palmer, E. TCR signaling requirements for activating T cells and for generating memory. Cell. Mol. Life Sci. 69, 1565-1575 (2012).
8. Jameson, S. C. & Masopust, D. Diversity in T cell memory: an embarrassment of riches. Immunity 31, 859-871 (2009).
9. Harari, A. et al. Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol. Rev. 211, 236-254 (2006).
10. Kuchroo, V. K., Anderson, A. C. & Petrovas, C. Coinhibitory receptors and CD8 T cell exhaustion in chronic infections. Curr. Opin. HIV AIDS 9, 439-445 (2014).
11. Chen, L. & Flies, D. B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nature Rev. Immunol. 13, 227-242 (2013).
12. Gallimore, A. et al. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J. Exp. Med. 187, 1383-1393 (1998).
13. Moskophidis, D., Lechner, F., Pircher, H. & Zinkernagel, R. M. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 362, 758-761 (1993).
14. Zajac, A. J. et al. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188, 2205-2213 (1998).
15. + T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nature Immunol. 10, 29-37 (2009).
16. Wherry, E. J. T cell exhaustion. Nature Immunol. 12, 492-499 (2011).
17. Klenerman, P. & Hill, A. T cells and viral persistence: lessons from diverse infections. Nature Immunol. 6, 873-879 (2005).
18. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nature Rev. Cancer 12, 252-264 (2012).
19. Kim, P. S. & Ahmed, R. Features of responding T cells in cancer and chronic infection. Curr. Opin. Immunol. 22, 223-230 (2010).
20. Crespo, J., Sun, H., Welling, T. H., Tian, Z. & Zou, W. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr. Opin. Immunol. 25, 214-221 (2013).
21. Wherry, E. J., Barber, D. L., Kaech, S. M., Blattman, J. N. & Ahmed, R. Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc. Natl Acad. Sci. USA 101, 16004-16009 (2004).
22. Virgin, H. W., Wherry, E. J. & Ahmed, R. Redefining chronic viral infection. Cell 138, 30-50 (2009).
23. Gairin, J. E., Mazarguil, H., Hudrisier, D. & Oldstone, M. B. Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes. J. Virol. 69, 2297-2305 (1995).
24. + T cell exhaustion during chronic viral infection. Immunity 27, 670-684 (2007).
25. Shin, H., Blackburn, S. D., Blattman, J. N. & Wherry, E. J. Viral antigen and extensive division maintain virus-specific CD8 T cells during chronic infection. J. Exp. Med. 204, 941-949 (2007).
26. Barber, D. L. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682-687 (2006).
27. Okazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S. & Honjo, T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nature Immunol. 14, 1212-1218 (2013).
28. Price, D. A. et al. T cell receptor recognition motifs govern immune escape patterns in acute SIV infection. Immunity 21, 793-803 (2004).
29. Walker, B. & McMichael, A. The T-cell response to HIV. Cold Spring Harb. Perspect. Med. 2, a007054 (2012).
30. + T cells with an effector phenotype and control of viral replication. Lancet 363, 863-866 (2004).
31. Ortiz, G. M. et al. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc. Natl Acad. Sci. USA 98, 13288-13293 (2001).
32. Fink, P. J. The biology of recent thymic emigrants. Annu. Rev. Immunol. 31, 31-50 (2013).
33. Douek, D. C. et al. Evidence for increased T cell turnover and decreased thymic output in HIV infection. J. Immunol. 167, 6663-6668 (2001).
34. +T-cell-mediated control of HIV-1 and SIV infection. Immunol. Res. 49, 135-146 (2011).
35. + lymphocytes. Science 283, 857-860 (1999).
36. + T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189, 991-998 (1999).
37. Hansen, S. G. et al. Immune clearance of highly pathogenic SIV infection. Nature 502, 100-104 (2013).
38. + T-cells from metastases are capable of antigen-specific degranulation and cytolysis directly ex vivo. Oncoimmunology 1, 467-530 (2012).
39. + T cells in metastases from melanoma patients. J. Clin. Invest. 121, 2350-2360 (2011).
40. Ahmadzadeh, M. et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114, 1537-1544 (2009).
41. Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. New Engl. J. Med. 348, 203-213 (2003).
42. Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964 (2006).
43. Fridman, W. H., Pages, F., Sautes-Fridman, C. & Galon, J. The immune contexture in human tumours: impact on clinical outcome. Nature Rev. Cancer 12, 298-306 (2012).
44. Blackburn, S. D. et al. Tissue-specific differences in PD-1 and PD-L1 expression during chronic viral infection: implications for CD8 T-cell exhaustion. J. Virol. 84, 2078-2089 (2010).
45. + T cells upregulate programmed death-1 expression during acute friend retrovirus infection but are highly cytotoxic and control virus replication. J. Immunol. 187, 3730-3737 (2011).
46. Larsen, M. et al. Exhausted cytotoxic control of Epstein-Barr virus in human lupus. PLoS Pathog. 7, e1002328 (2011).
47. + T cells in HIV infection. PLoS ONE 7, e40146 (2012).
48. + T cell dysfunction in melanoma patients. J. Exp. Med. 207, 2175-2186 (2010).
49. Jin, H. T. et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc. Natl Acad. Sci. USA 107, 14733-14738 (2010).
50. Nakamoto, N. et al. Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog. 5, e1000313 (2009).
51. Sakuishi, K. et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207, 2187-2194 (2010).
52. Woo, S. R. et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72, 917-927 (2012).
53. Blackburn, S. D., Shin, H., Freeman, G. J. & Wherry, E. J. Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockade. Proc. Natl Acad. Sci. USA 105, 15016-15021 (2008).
54. + cytotoxic T-cell responses during chronic viral infection. J. Virol. 68, 8056-8063 (1994).
55. Snyder, C. M. et al. Memory inflation during chronic viral infection is maintained by continuous production of short-lived, functional T cells. Immunity 29, 650-659 (2008).
56. + T lymphocytes during active, latent, and resolved infection and its relation with CD57. J. Immunol. 174, 6088-6094 (2005).
57. Hislop, A. D., Taylor, G. S., Sauce, D. & Rickinson, A. B. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu. Rev. Immunol. 25, 587-617 (2007).
58. Freeman, M. L., Burkum, C. E., Jensen, M. K., Woodland, D. L. & Blackman, M. A. γ-Herpesvirus reactivation differentially stimulates epitope-specific CD8 T cell responses. J. Immunol. 188, 3812-3819 (2012).
59. + T cells vary in differentiation phenotype in different persistent virus infections. Nature Med. 8, 379-385 (2002).
60. + T cell differentiation. J. Clin. Invest. 120, 4077-4090 (2010).
61. + T cells after early HIV-1 infection. J. Virol. 81, 4199-4214 (2007).
62. Vigano, S. et al. Rapid perturbation in viremia levels drives increases in functional avidity of HIV-specific CD8 T cells. PLoS Pathog. 9, e1003423 (2013).
63. Utzschneider, D. T. et al. T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nature Immunol. 14, 603-610 (2013).
64. + T cells. Immunity 35, 400-412 (2011).
65. Youngblood, B. et al. Cutting edge: Prolonged exposure to HIV reinforces a poised epigenetic program for PD-1 expression in virus-specific CD8 T cells. J. Immunol. 191, 540-544 (2013).
66. + T cells during acute HCV infection, irrespective of clinical outcome. J. Virol. 82, 3154-3160 (2008).
67. Wherry, E. J., Blattman, J. N., Murali-Krishna, K., van der Most, R. & Ahmed, R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77, 4911-4927 (2003).
68. + T cells. Science 340, 635-639 (2013).
69. + T cell immunity. Science 340, 630-635 (2013).
70. Williams, M. A. & Bevan, M. J. Effector and memory CTL differentiation. Annu. Rev. Immunol. 25, 171-192 (2007).
71. + T cells cooperate to contain chronic viral infection. Science 338, 1220-1225 (2012).
72. Sun, J. C. & Bevan, M. J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300, 339-342 (2003).
73. Waggoner, S. N., Cornberg, M., Selin, L. K. & Welsh, R. M. Natural killer cells act as rheostats modulating antiviral T cells. Nature 481, 394-398 (2012).
74. Angelosanto, J. M., Blackburn, S. D., Crawford, A. & Wherry, E. J. Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection. J. Virol. 86, 8161-8170 (2012).
75. + T cell exhaustion versus memory. Immunity 37, 1130-1144 (2012).
76. Cornberg, M. et al. Clonal exhaustion as a mechanism to protect against severe immunopathology and death from an overwhelming CD8 T cell response. Frontiers Immunol. 4, 475 (2013).
77. + T cells to persistent antigen. Nature Immunol. 14, 1173-1182 (2013).
78. Frebel, H. et al. Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice. J. Exp. Med. 209, 2485-2499 (2012).
79. Mueller, S. N. et al. PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice. J. Clin. Invest. 120, 2508-2515 (2010).
80. Hirano, F. et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 65, 1089-1096 (2005).
81. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New Engl. J. Med. 366, 2443-2454 (2012).
82. Iwai, Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99, 12293-12297 (2002).
83. Wakim, L. M., Waithman, J., van Rooijen, N., Heath, W. R. & Carbone, F. R. Dendritic cell-induced memory T cell activation in nonlymphoid tissues. Science 319, 198-202 (2008).
84. Gebhardt, T. et al. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nature Immunol. 10, 524-530 (2009).
85. RM cells providing global skin immunity. Nature 483, 227-231 (2012).
86. Mueller, S. N., Gebhardt, T., Carbone, F. R. & Heath, W. R. Memory T cell subsets, migration patterns, and tissue residence. Annu. Rev. Immunol. 31, 137-161 (2013).
87. Wakim, L. M. et al. The molecular signature of tissue resident memory CD8 T cells isolated from the brain. J. Immunol. 189, 3462-3471 (2012).
88. + skin-resident T cells in human herpes virus infection. Nature 497, 494-497 (2013).
89. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl. J. Med. 363, 711-723 (2010).
90. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New Engl. J. Med. 366, 2455-2465 (2012).
91. Ribas, A. Tumor immunotherapy directed at PD-1. New Engl. J. Med. 366, 2517-2519 (2012).
92. Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. New Engl. J. Med. 369, 134-144 (2013).
93. Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. New Engl. J. Med. 369, 122-133 (2013).
94. Riley, J. L. Combination checkpoint blockade-taking melanoma immunotherapy to the next level. New Engl. J. Med. 369, 187-189 (2013).
95. Korman, A. J., Peggs, K. S. & Allison, J. P. Checkpoint blockade in cancer immunotherapy. Adv. Immunol. 90, 297-339 (2006).
96. Gardiner, D. et al. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS ONE 8, e63818 (2013).
97. Fuller, M. J. et al. Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). Proc. Natl Acad. Sci. USA 110, 15001-15006 (2013).
98. Velu, V. et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458, 206-210 (2009).
99. Minter, S., Willner, I. & Shirai, K. Ipilimumab-induced hepatitis C viral suppression. J. Clin. Oncol. 31, e307-e308 (2013).